Analyst Ratings For Dermira Inc (NASDAQ:DERM)
Today, Dermira Inc (NASDAQ:DERM) stock received an upgrade by Raymond James from Underperform to Market Perform.
There are 5 Buy Ratings, 2 Hold Ratings, no Strong Buy Ratings, no Sell Ratings on the stock.
The current consensus rating on Dermira Inc (NASDAQ:DERM) is Buy with a consensus target price of $23.1667 per share, a potential 245.77% upside.
Some recent analyst ratings include
- 1/17/2019-Dermira Inc (NASDAQ:DERM) gets upgraded to Market Perform by Raymond James
- 11/20/2018-Dermira Inc (NASDAQ:DERM) had its Buy ➝ Buy rating reiterated by Guggenheim with a $20.00 price target
- 10/2/2018-Dermira Inc (NASDAQ:DERM) had its Hold rating reiterated by Mizuho with a $10.00 price target
- 3/22/2018-Dermira Inc (NASDAQ:DERM) had its Outperform rating reiterated by Leerink Swann
- On 10/19/2018 Matthew K Fust, Director, sold 4,000 with an average share price of $13.75 per share and the total transaction amounting to $55,000.00.
- On 7/9/2018 Thomas G. Wiggans, CEO, bought 12,000 with an average share price of $10.00 per share and the total transaction amounting to $120,000.00.
- On 7/2/2018 Thomas G. Wiggans, CEO, bought 13,780 with an average share price of $8.71 per share and the total transaction amounting to $120,023.80.
- On 6/25/2018 Thomas G. Wiggans, CEO, bought 12,150 with an average share price of $9.84 per share and the total transaction amounting to $119,556.00.
- On 6/18/2018 Thomas G. Wiggans, CEO, bought 11,875 with an average share price of $10.10 per share and the total transaction amounting to $119,937.50.
- On 3/1/2018 David E Cohen, Director, sold 600 with an average share price of $25.85 per share and the total transaction amounting to $15,510.00.
- On 3/1/2018 Eugene A Bauer, Insider, sold 500 with an average share price of $25.32 per share and the total transaction amounting to $12,660.00.
About Dermira Inc (NASDAQ:DERM)
Dermira, Inc., a biopharmaceutical company, identifies, develops, and commercializes therapies to treat dermatologic diseases. The company's product candidates include Glycopyrronium tosylate, a novel form of an anticholinergic agent that has completed Phase III clinical trial for the treatment of primary axillary hyperhidrosis; Olumacostat glasaretil, a novel small molecule designed to target sebum production, which is in Phase III clinical trial for the treatment of acne vulgaris; and lebrikizumab, a novel humanized monoclonal antibody targeting interleukin 13 that is in Phase 2b development for the treatment of moderate-to-severe atopic dermatitis. It has licensing agreements with Maruho Co., Ltd. to develop and commercialize glycopyrronium tosylate in Japan; and F. Hoffmann-La Roche Ltd and Genentech, Inc. to develop and commercialize lebrikizumab. The company was formerly known as Skintelligence, Inc. and changed its name to Dermira, Inc. in September 2011. Dermira, Inc. was founded in 2010 and is headquartered in Menlo Park, California.
Recent Trading Activity for Dermira Inc (NASDAQ:DERM)
Shares of Dermira Inc closed the previous trading session at 6,70 −0,10 1,47 % with 6.88 shares trading hands.